Cargando…

Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC)

AIMS: We examined the effects of istaroxime in patients hospitalized for acute heart failure (AHF) related Society for Cardiovascular Angiography and Interventions (SCAI) stage B pre‐cardiogenic shock (CS). METHODS AND RESULTS: Sixty patients with AHF without acute myocardial infarction with pre‐CS,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metra, Marco, Chioncel, Ovidiu, Cotter, Gad, Davison, Beth, Filippatos, Gerasimos, Mebazaa, Alexandre, Novosadova, Maria, Ponikowski, Piotr, Simmons, Phillip, Soffer, Joseph, Simonson, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	Focused Issue on Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804717/ https://www.ncbi.nlm.nih.gov/pubmed/35867804 http://dx.doi.org/10.1002/ejhf.2629

Ejemplares similares

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
por: Metra, Marco, et al.
Publicado: (2010)

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF
por: Voors, Adriaan A, et al.
Publicado: (2014)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) trial design
por: Bartunek, Jozef, et al.
Publicado: (2015)

Cellular Mechanisms Underlying the Low Cardiotoxicity of Istaroxime
por: Racioppi, María Florencia, et al.
Publicado: (2021)

Istaroxime: A rising star in acute heart failure
por: Aditya, Suruchi, et al.
Publicado: (2012)

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Medical Therapy of Heart Failure with Reduced Ejection Fraction—A Call for Comparative Research
por: Cotter, Gad, et al.
Publicado: (2021)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study
por: Meyer, Sven, et al.
Publicado: (2016)

Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial
por: Biegus, Jan, et al.
Publicado: (2019)

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure
por: Forzano, Imma, et al.
Publicado: (2022)

Rationale and design of Ferinject(®) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia
por: Anker, Stefan D., et al.
Publicado: (2009)

Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial
por: Pocock, Stuart J., et al.
Publicado: (2022)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF
por: Davison, Beth A., et al.
Publicado: (2011)

Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Global differences in acute heart failure treatment: analysis of the STRONG‐HF site feasibility questionnaire
por: Novosadova, Maria, et al.
Publicado: (2023)

Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial
por: Takagi, Koji, et al.
Publicado: (2021)

Clinical development plan for regenerative therapy in heart failure
por: Terzic, Andre, et al.
Publicado: (2016)

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF
por: Liu, Licette C. Y., et al.
Publicado: (2016)

Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature
por: Radu, Razvan I., et al.
Publicado: (2021)

Cerebral flow variation at different intra-aortic balloon settings in cardiogenic shock
por: Colombo, Costanza Natalia Julia, et al.
Publicado: (2022)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Extracorporeal Membrane Oxygenation (ECMO) Rescue Therapy in Post-cardiotomy Cardiogenic Shock: A Case Report
por: Stefan, Mihai, et al.
Publicado: (2020)

Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy
por: Kamel, S. M., et al.
Publicado: (2021)

Safety and Efficacy of Istaroxime in Patients With Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
por: Khalid Khan, Saad, et al.
Publicado: (2023)

Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF
por: Mogensen, Ulrik M., et al.
Publicado: (2017)

Chloroquine Cardiotoxicity Leading to Cardiogenic Shock
por: Alder, Madeleine, et al.
Publicado: (2020)

The “Right” Side of Cardiogenic Shock
por: Brailovsky, Yevgeniy, et al.
Publicado: (2020)

Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium
por: Wallner, Markus, et al.
Publicado: (2017)

Occludin is overexpressed in Alzheimer's disease and vascular dementia
por: Romanitan, Mihaela Oana, et al.
Publicado: (2007)

Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry
por: Kapelios, Chris J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n8b29e3pjh0cp9jtd3gafq68m4